Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00813_DB00872> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00813_DB00872 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00813_DB00872 label "DDI between Fentanyl and Conivaptan - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate. [drugbank_resource:DB00813_DB00872]" assertion.
- drugbank_resource:DB00813_DB00872 identifier "drugbank_resource:DB00813_DB00872" assertion.
- drugbank_resource:DB00813_DB00872 title "DDI between Fentanyl and Conivaptan - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate." assertion.